Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | PGR | P06401 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
| ▸ | FNTB | P49356 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | SQLE | Q14534 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837840 | 1.00 | NR1I2 (0.93) | NR1I2LMNAPGRKMT2AFNTA | |
| SCHEMBL2832254 | 1.00 | NR1I2 (0.93) | NR1I2LMNAPGRKMT2AFNTA | |
| SCHEMBL2836986 | 1.00 | NR1I2 (0.93) | NR1I2LMNAPGRKMT2AFNTA | |
| SCHEMBL111036 | 1.00 | NR1I2 (0.93) | NR1I2LMNAPGRKMT2AFNTA | |
| SCHEMBL2834897 | 1.00 | NR1I2 (0.93) | NR1I2LMNAPGRKMT2AFNTA | |
| SCHEMBL30578160 | 1.00 | NR1I2 (0.93) | NR1I2LMNAPGRKMT2AFNTA | |
| SCHEMBL29852311 | 0.98 | NR1I2 (0.89) | NR1I2LMNAPGRKMT2AFNTA | |
| SCHEMBL2835876 | 0.96 | NR1I2 (0.86) | NR1I2LMNAPGRKMT2AFNTA | |
| SCHEMBL2833787 | 0.96 | NR1I2 (1.00) | NR1I2LMNAPGRKMT2AFNTA | |
| Lycopene SCHEMBL21485499 | 0.96 | NR1I2 (1.00) | NR1I2LMNAPGRKMT2AFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | claimed |
| US-20260130395-A1 | Water Dispersible Botanical Compositions | AQUILA BLACK LTD (AU) | 2026-05-14 | — | — | US | claimed |
| EP-4702154-A2 | METHODS AND COMPOSITIONS FOR PRODUCING A CAROTENOID OR TERPENOID | Allozymes Pte Ltd (SG) | 2026-03-04 | — | — | EP | claimed |
| US-12365945-B2 | Urinary microbiomic profiling | Convergent Genomics, Inc. (US) | 2025-07-22 | — | — | US | claimed |
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | UNIVERSITY OF NOTRE DAME DU LAC | 2025-01-09 | — | — | US | claimed |
| WO-2024215256-A2 | METHODS AND COMPOSITIONS | ALLOZYMES PTE LTD (SG) | 2024-10-17 | — | — | WO | claimed |
| US-20240180802-A1 | USE OF NEUROSPORENE TO PROTECT THE SKIN FROM THE HARMFUL EFFECTS OF BLUE LIGHT | DEINOVE (FR) | 2024-06-06 | — | — | US | claimed |
| US-20230310461-A1 | Compositions and Methods for Treatment of Prediabetes | CROSS III WILLIAM H (US) | 2023-10-05 | — | — | US | claimed |
| US-20230210788-A1 | USES OF A CAROTENOID IN THE TREATMENT OR PREVENTION OF STRESS INDUCED CONDITIONS | GAT THERAPEUTICS, S.L. (ES) | 2023-07-06 | — | — | US | claimed |
| US-20230181490-A1 | PRO-LYCOPENE RICH COMPOSITION AND METHODS OF USING SAME | LYCORED LTD. (IL) | 2023-06-15 | — | — | US | claimed |
| WO-2004056974-A2 | MUTATIONS AFFECTING CAROTENOID PRODUCTION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2004-07-08 | — | — | WO | claimed |
| WO-2004052085-A1 | TRANSGENIC PINEAPPLE PLANTS WITH MODIFIED CAROTENOID LEVELS AND METHODS OF THEIR PRODUCTION | DEL MONTE FRESH PRODUCE COMPANY (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040077068-A1 | Use of microorganisms which metabolize single carbon substrates for the production of carotenoid compounds in high yields | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-04-22 | — | — | US | claimed |
| WO-2003074670-A2 | LIS PROMOTER FOR EXPRESSION OF TRANSGENES IN FLORAL TISSUES | BALL HORTICULTURAL COMPANY (US) | 2003-09-12 | — | — | WO | claimed |
| US-20030143660-A1 | Method for production of asymmetric carotenoids | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-07-31 | — | — | US | claimed |
| EP-1328639-A2 | CAROTENOID PRODUCTION BY RECOMBINANT, C1-METABOLIZING METHANOTROPHIC BACTERIA | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2003-07-23 | — | — | EP | claimed |
| WO-2003044205-A1 | METHOD FOR PRODUCTION OF ASYMMETRIC CAROTENOIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-05-30 | — | — | WO | claimed |
| US-20030003528-A1 | Carotenoid production from a single carbon substrate | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-01-02 | — | — | US | claimed |
| WO-2002018617-A2 | CAROTENOID PRODUCTION BY RECOMBINANT, C1-METABOLIZING METHANOTHROPIC BACTERIA | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2002-03-07 | — | — | WO | claimed |
| CN-1227609-A | Process for producing carotenoid compounds and specialty oils in plant seeds | CALGENE INC (US) | 1999-09-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180802-A1 | USE OF NEUROSPORENE TO PROTECT THE SKIN FROM THE HARMFUL EFFECTS OF BLUE LIGHT | CRY1, CRY2, CUTA | NR1I2 495/4885LMNA 3424/4885PGR 981/4885 |
| US-20260130395-A1 | Water Dispersible Botanical Compositions | TTPA, PNLIP, SRMS | NR1I2 4147/4885LMNA 1292/4885PGR 3420/4885 |
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | MGAM, OPRM1, BPGM | NR1I2 1375/4885LMNA 3928/4885PGR 3951/4885 |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | NR1I2 572/4885LMNA 259/4885PGR 1205/4885 |
| US-20230310461-A1 | Compositions and Methods for Treatment of Prediabetes | GPX1, GPX4, NFE2L2 | NR1I2 1496/4885LMNA 417/4885PGR 2020/4885 |
| US-20230210788-A1 | USES OF A CAROTENOID IN THE TREATMENT OR PREVENTION OF STRESS INDUCED CONDITIONS | NR3C1, MC5R, MC1R | NR1I2 284/4885LMNA 1560/4885PGR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.